Roxadustat ― new therapeutic option for treatment of anemia in patients with chronic kidney disease
Open Access
- 30 June 2022
- journal article
- Published by VM Media Group sp. z o.o in Renal Disease and Transplantation Forum
- Vol. 15 (2) , 63-74
Abstract
Chronic kidney disease (CKD) is an increasingly common public health issue. It is estimated that it affects 8–16% of the global population. Anemia is a very common complication of chronic kidney disease, and its occurrence is associated with a reduced quality of life, increased morbidity, and mortality. The main causes of CKD anemia include erythropoietin (EPO) deficiency and iron deficiency (absolute and functional). In addition, the bone marrow response to EPO is reduced in patients with chronic inflammation, which is often present in patients with advanced stages of CKD and dialyzed patients. According to the current guidelines, the treatment of anemia in CKD involves recombinant erythropoiesis-stimulating agents (ESAs) along with iron supplementation. In some patients, intensive correction of anemia requiring high doses of ESA and intravenous iron may increase the risk of adverse events. The correction also requires injections, outpatient visits, and hospital stays, which is especially troublesome for pre-dialysis patients. The discovery of hypoxia-inducible factors (HIFs) responsible for stimulating cells to EPO synthesis and increased activity of oxygen-dependent genes enabled the development of new drugs, so-called HIF-PHI inhibitors (hypoxia-inducible factor-prolyl hydroxylase inhibitors, prolyl hydroxylase inhibitors). Those compounds reversibly inhibit the activityof the enzyme responsible for inactivating the HIF and thus increase endogenous EPO synthesis and affect iron metabolism. This discovery opened new options for the treatment of anemia in CKD patients. Phase 2 and 3 clinical trials are conducted with several drugs: daprodustat (GSK-1278863), roxadustat (FG-4592), and wadadustat (AKB-6548). To date, only roxadustat has been approved for treatment of CKD-related anemia. Roxadustat (FG-4592) is a novel orally active, potent, and reversible inhibitor of prolyl hydroxylase (PHI), causing functional activation of target genes that encode proteins such as EPO, EPO receptor, heme biosynthesis enzymes, and proteins that enhance iron absorption and transport and thus promote formation and maturation of red blood cells (RBCs). This study aims to summarize the available results of studies on the use of roxadustat in Keywords: chronic kidney disease anemia erythropoiesis stimulating agents prolyl hydroxylase inhibitorsKeywords
This publication has 42 references indexed in Scilit:
- Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)Advances in Therapy, 2021
- Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 StudiesAdvances in Therapy, 2021
- Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKDKidney International Reports, 2021
- A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS StudyKidney International Reports, 2021
- Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) ConferenceKidney International, 2021
- RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to DialysisKidney International Reports, 2021
- Roxadustat for CKD-related Anemia in Non-dialysis PatientsKidney International Reports, 2021
- Roxadustat: First Global ApprovalDrugs, 2019
- Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysisJournal of Pharmaceutical and Biomedical Analysis, 2013
- C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl HydroxylationCell, 2001